Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The Role of Thalidomide in Reversing Cachexia in Patients with Oesophageal Cancer
ISRCTN ISRCTN23944748
ClinicalTrials.gov identifier
Public title The Role of Thalidomide in Reversing Cachexia in Patients with Oesophageal Cancer
Scientific title
Acronym N/A
Serial number at source SDAH/2000/009
Study hypothesis Thalidomide increases weight (mainly lean body mass). This effect is mediated by suppression of tumour necrosis factor.
Lay summary Not provided at time of registration
Ethics approval Approved by the Derbyshire Research Ethics Committee on 13/12/2000, reference number: 0003/150
Study design Double-blind placebo controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Oesophageal cancer
Participants - inclusion criteria Adults with non-obstructing and inoperable oesophageal cancer (dysphagia score <3, able to swallow a semi-solid diet)
Participants - exclusion criteria 1. Pre-menopausal women
2. Patients receiving any adjuvant chemotherapy or radiotherapy
3. Patients with oesophageal obstruction
4. Those with established neuropathy
5. Patients requiring frequent laser ablation sessions
6. Those unable to maintain an adequate caloric intake
7. Increased debility
Anticipated start date 10/12/2002
Anticipated end date 16/06/2006
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 34
Interventions Thalidomide versus placebo
Primary outcome measure(s) Change in lean body mass
Secondary outcome measure(s) 1. Change in resting energy expenditure
2. Change in total body weight
Sources of funding The research was funded in part by the MAGIC appeal (registered charity number: 1061812) and in part by matched funds from Derby Hospitals Research and Development grant scheme.
Trial website
Publications
Contact name Dr  Jan  Freeman
  Address Derby Hospitals NHS Foundation Trust
Derby City Hospital
Uttoxeter Road
  City/town Derby
  Zip/Postcode DE22 3NE
  Country United Kingdom
Sponsor Derby Hospitals NHS Foundation Trust (UK)
  Address Derby City Hospital
Uttoxeter Road
  City/town Derby
  Zip/Postcode DE22 3NE
  Country United Kingdom
  Tel +44 (0)1332 340 131
  Email Kirsty.Murdoch@derbyhospitals.nhs.uk
Date applied 28/04/2006
Last edited 09/05/2012
Date ISRCTN assigned 06/06/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central